Arovella Therapeutics (formerly SUDA Pharmaceuticals) has announced it has in-licensed the rights to a novel monoclonal antibody that targets the Dickkopf-1 (DKK1) peptide from MD Anderson Cancer Center (for undisclosed upfront and development milestones as well as single digit royalties). DKK1 has been shown to promote tumour metastasis across a variety of tumour types. The company plans to combine the DKK1 targeting technology with its recently acquired invariant natural killer T (iNKT) cell t ....
21 Dec 2021
Arovella Therapeutics - Acquiring DKK1 rights
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Arovella Therapeutics - Acquiring DKK1 rights
Arovella Therapeutics Limited (ALA:ASX) | 0 0 6.7% | Mkt Cap: 19.5m
- Published:
21 Dec 2021 -
Author:
Maxim Jacobs -
Pages:
5
Arovella Therapeutics (formerly SUDA Pharmaceuticals) has announced it has in-licensed the rights to a novel monoclonal antibody that targets the Dickkopf-1 (DKK1) peptide from MD Anderson Cancer Center (for undisclosed upfront and development milestones as well as single digit royalties). DKK1 has been shown to promote tumour metastasis across a variety of tumour types. The company plans to combine the DKK1 targeting technology with its recently acquired invariant natural killer T (iNKT) cell t ....